Literature DB >> 26904573

Immunological interactions in radiotherapy-opening a new window of opportunity.

Tapesh Bhattacharyya1, Kiran Purushothaman1, Sanudev Sadanandan Vadakke Puthiyottil1, Atanu Bhattacharjee1, Geetha Muttah1.   

Abstract

After a span of significant developments & advances we have reached a plateau in all the oncological disciplines in last decade. Escalation of dose of radiotherapy (RT) became possible with emergence of intensity modulated radiotherapy (IMRT) and image guided radiotherapy (IGRT). Different radiosensitizing agents starting from conventional cytotoxic drugs to hypoxic radiosensitizers have been tried to increase the effect of RT. However technological advancement hasn't been translated into significant clinical benefits. Exploiting the immune system to enhance the effect of RT is a relatively new concept and a fast growing area in the field of oncology. RT cannot longer be considered as a localized treatment, but rather as a systemic weapon for solid tumors. The phenomenon of abscopal effect, meaning the action of RT upon distant 'out-of-field' foci of malignancies has been a major focus of recent research, and holds great promise for the future. In this review article we are going to discuss the immunological interactions in RT and its promising clinical implications.

Entities:  

Keywords:  Immunology; PD-L1; cytotoxic T lymphocyte antigen-4 (CTLA-4); radiotherapy (RT)

Year:  2016        PMID: 26904573      PMCID: PMC4739993          DOI: 10.3978/j.issn.2305-5839.2015.10.44

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  26 in total

1.  The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells.

Authors:  G B Cohen; R T Gandhi; D M Davis; O Mandelboim; B K Chen; J L Strominger; D Baltimore
Journal:  Immunity       Date:  1999-06       Impact factor: 31.745

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 3.  Radiation as an immune modulator.

Authors:  Byron Burnette; Ralph R Weichselbaum
Journal:  Semin Radiat Oncol       Date:  2013-10       Impact factor: 5.934

4.  Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.

Authors:  Kwan-Hwa Chi; Shih-Jen Liu; Chung-Pin Li; Hsu-Ping Kuo; Yu-Shan Wang; Yee Chao; Shih-Liang Hsieh
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

5.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

Review 6.  MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.

Authors:  Joseph D Comber; Ramila Philip
Journal:  Ther Adv Vaccines       Date:  2014-05

Review 7.  Combination of radiotherapy and immune checkpoint inhibitors.

Authors:  Karsten A Pilones; Claire Vanpouille-Box; Sandra Demaria
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

8.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Authors:  S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer
Journal:  Ann Oncol       Date:  2013-03-27       Impact factor: 32.976

9.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701

10.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Authors:  Anna R Kwilas; Renee N Donahue; Michael B Bernstein; James W Hodge
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

View more
  6 in total

1.  Complementing the tumor-specific immunity in tumor radiotherapy.

Authors:  Linjie Zhao; Shengtao Zhou
Journal:  Ann Transl Med       Date:  2016-08

2.  The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Joanne B Weidhaas; Jonathan Harris; Dörthe Schaue; Allen M Chen; Robert Chin; Rita Axelrod; Adel K El-Naggar; Anurag K Singh; Thomas J Galloway; David Raben; Dian Wang; Chance Matthiesen; Vilija N Avizonis; Rafael R Manon; Omar Yumen; Phuc Felix Nguyen-Tan; Andy Trotti; Heath Skinner; Qiang Zhang; Robert L Ferris; David Sidransky; Christine H Chung
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

3.  Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study.

Authors:  L Basler; N Andratschke; S Ehrbar; M Guckenberger; S Tanadini-Lang
Journal:  Radiat Oncol       Date:  2018-01-22       Impact factor: 3.481

Review 4.  Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.

Authors:  Mandy van Gulijk; Floris Dammeijer; Joachim G J V Aerts; Heleen Vroman
Journal:  Front Immunol       Date:  2018-12-05       Impact factor: 7.561

Review 5.  Immune targets in the tumor microenvironment treated by radiotherapy.

Authors:  Omer M Ozpiskin; Lu Zhang; Jian Jian Li
Journal:  Theranostics       Date:  2019-01-30       Impact factor: 11.556

Review 6.  Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.

Authors:  Sara Nava; Daniela Lisini; Simona Frigerio; Anna Bersano
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.